Modeling of human cardiomyopathy with induced pluripotent stem cells

Journal of Biomedical Nanotechnology

Volumn 10, Issue 10, 2014, Pages 2562-2585

  Lee, Yee Ki ^a   Ng, Kwong Man ^a,b   Tse, Hung Fat ^a,b,c,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (China)

^d Chinese Academy of Sciences   (Hong Kong)

Author keywords

Cardiomyocytes; Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Induced pluripotent stem cell

Indexed keywords

CARDIOLOGY;

CARDIOMYOCYTES; CYSTIC FIBROSIS; DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; INDUCED PLURIPOTENT STEM CELLS; INHERITED DISEASE; MECHANISTIC STUDIES; PATIENT SPECIFIC;

STEM CELLS;

CALCIUM;

CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOMYOPATHY; CELL DIFFERENTIATION; CELL STRUCTURE; CHANNELOPATHY; CONGESTIVE CARDIOMYOPATHY; DISEASE MODEL; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO GENE TRANSFER; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; REVIEW; SKIN FIBROBLAST; TISSUE STRUCTURE; BIOLOGICAL MODEL; PATHOLOGY; PATHOPHYSIOLOGY;

CARDIOMYOPATHIES; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; MYOCARDIAL CONTRACTION;

EID: 84905659258     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1986     Document Type: Review

References (212)

1. B. J. Maron, J. A. Towbin, G. Thiene, C. Antzelevitch, D. Corrado, D. Arnett, A. J. Moss, C. E. Seidman, J. B. Young, A. American Heart, H. F. Council on Clinical Cardiology, C. Transplantation, C. Quality of, R. Outcomes, G. Functional, G. Translational Biology Interdisciplinary Working, E. Council on, and Prevention, Contemporary definitions and classification of the cardiomyopathies: An American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 113, 1807 (2006).
2. B. Maisch, M. Noutsias, V. Ruppert, A. Richter, and S. Pankuweit, Cardiomyopathies: Classification, diagnosis, and treatment. Heart. Fail. Clin. 8, 53 (2012).
3. D. Jacoby and W. J. McKenna, Genetics of inherited cardiomyopathy. Eur Heart J. 33, 296 (2012).
4. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K.Tomoda, and S.Yamanaka, Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861 (2007).
5. M. Nakagawa, M. Koyanagi, K. Tanabe, K. Takahashi, T. Ichisaka, T. Aoi, K. Okita, Y. Mochiduki, N. Takizawa, and S. Yamanaka, Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26, 101 (2008).
6. K. Takahashi and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663 (2006).
7. A. Moretti, M. Bellin, A. Welling, C. B. Jung, J. T. Lam, L. Bott-Flugel, T. Dorn, A. Goedel, C. Hohnke, F. Hofmann, M. Seyfarth, D. Sinnecker, A. Schomig, and K. L. Laugwitz, Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397 (2010).
8. N. Sun, M. Yazawa, J. Liu, L. Han, V. Sanchez-Freire, O. J. Abilez, E. G. Navarrete, S. Hu, L. Wang, A. Lee, A. Pavlovic, S. Lin, R. Chen, R. J. Hajjar, M. P. Snyder, R. E. Dolmetsch, M. J. Butte, E. A. Ashley, M. T. Longaker, R. C. Robbins, and J. C. Wu, Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra147 (2012).
9. D. Ma, H. Wei, Y. Zhao, J. Lu, G. Li, N. B. Sahib, T. H. Tan, K. Y. Wong, W. Shim, P. Wong, S. A. Cook, and R. Liew, Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int. J. Cardiol. 168, 5277 (2013).
10. A. L. Lahti, V. J. Kujala, H. Chapman, A. P. Koivisto, M. Pekkanen-Mattila, E. Kerkela, J. Hyttinen, K. Kontula, H. Swan, B. R. Conklin, S. Yamanaka, O. Silvennoinen, and K. Aalto-Setala, Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 5, 220 (2012).
11. F. Lan, A. S. Lee, P. Liang, V. Sanchez-Freire, P. K. Nguyen, L. Wang, L. Han, M. Yen, Y. Wang, N. Sun, O. J. Abilez, S. Hu, A. D. Ebert, E. G. Navarrete, C. S. Simmons, M. Wheeler, B. Pruitt, R. Lewis, Y. Yamaguchi, E. A. Ashley, D. M. Bers, R. C. Robbins, M. T. Longaker, and J. C. Wu, Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 12, 101 (2013).
12. T. Cermak, E. L. Doyle, M. Christian, L. Wang, Y. Zhang, C. Schmidt, J. A. Baller, N. V. Somia, A. J. Bogdanove, and D. F. Voytas, Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011).
13. M. Christian, T. Cermak, E. L. Doyle, C. Schmidt, F. Zhang, A. Hummel, A. J. Bogdanove, and D. F. Voytas, Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757 (2010).
14. J. C. Miller, S. Tan, G. Qiao, K. A. Barlow, J. Wang, D. F. Xia, X. Meng, D. E. Paschon, E. Leung, S. J. Hinkley, G. P. Dulay, K. L. Hua, I. Ankoudinova, G. J. Cost, F. D. Urnov, H. S. Zhang, M. C. Holmes, L. Zhang, P. D. Gregory, and E. J. Rebar, A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143 (2011).
15. I. Splawski, K. W. Timothy, L. M. Sharpe, N. Decher, P. Kumar, R. Bloise, C. Napolitano, P. J. Schwartz, R. M. Joseph, K. Condouris, H. Tager-Flusberg, S. G. Priori, M. C. Sanguinetti, and M. T. Keating, Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19 (2004).
16. W. H. Thiel, B. Chen, T. J. Hund, O. M. Koval, A. Purohit, L. S. Song, P. J. Mohler, and M. E. Anderson, Proarrhythmic defects in timothy syndrome require calmodulin kinase II. Circulation 118, 2225 (2008).
17. E. P. Cheng, C. Yuan, M. F. Navedo, R. E. Dixon, M. Nieves-Cintron, J. D. Scott, and L. F. Santana, Restoration of normal L-type Ca2+ channel function during Timothy syndrome by ablation of an anchoring protein. Circ. Res. 109, 255 (2011).
18. F. Ahmad, S. K. Banerjee, M. L. Lage, X. N. Huang, S. H. Smith, S. Saba, J. Rager, D. A. Conner, A. M. Janczewski, K. Tobita, J. P. Tinney, I. P. Moskowitz, A. R. Perez-Atayde, B. B. Keller, M. A. Mathier, S. G. Shroff, C. E. Seidman, and J. G. Seidman, The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy. PLoS One 3, e2642 (2008).
19. R. Lombardi, A. Bell, V. Senthil, J. Sidhu, M. Noseda, R. Roberts, and A. J. Marian, Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc. Res. 79, 109 (2008).
20. S. C. Menon, V. V. Michels, P. A. Pellikka, J. D. Ballew, M. L. Karst, K. J. Herron, S. M. Nelson, R. J. Rodeheffer, and T. M. Olson, Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology. Clin. Genet. 74, 445 (2008).
21. C. D. Ramirez and R. Padron, Familial hypertrophic cardiomyopathy: Genes, mutations and animal models. A review. Invest. Clin. 45, 69 (2004).
22. P. L. Bader, M. Faizi, L. H. Kim, S. F. Owen, M. R. Tadross, R. W. Alfa, G. C. Bett, R. W. Tsien, R. L. Rasmusson, and M. Shamloo, Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc. Natl. Acad. Sci. U.S.A. 108, 15432 (2011).
23. J. Kwon, N. Lee, I. Jeon, H. J. Lee, J. T. Do, D. R. Lee, S. H. Oh, D. A. Shin, A. Kim, and J. Song, Neuronal differentiation of a human induced pluripotent stem cell line (FS-1) derived from newborn foreskin fibroblasts. Int. J. Stem Cells. 5, 140 (2012).
24. S. J. Kattman, A. D. Witty, M. Gagliardi, N. C. Dubois, M. Niapour, A. Hotta, J. Ellis, and G. Keller, Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. 8, 228 (2011).
25. C. Kim, J. Wong, J. Wen, S. Wang, C. Wang, S. Spiering, N. G. Kan, S. Forcales, P. L. Puri, T. C. Leone, J. E. Marine, H. Calkins, D. P. Kelly, D. P. Judge, and H. S. Chen, Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494, 105 (2013).
26. I. Itzhaki, L. Maizels, I. Huber, L. Zwi-Dantsis, O. Caspi, A. Winterstern, O. Feldman, A. Gepstein, G. Arbel, H. Hammerman, M. Boulos, and L. Gepstein, Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225 (2011).
27. M. Yazawa and R. E. Dolmetsch, Modeling Timothy syndrome with iPS cells. J. Cardiovasc. Transl. Res. 6, 1 (2013).
28. E. Matsa, D. Rajamohan, E. Dick, L. Young, I. Mellor, A. Staniforth, and C. Denning, Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 32, 952 (2011).
29. A. Novak, R. Shtrichman, I. Germanguz, H. Segev, N. Zeevi-Levin, B. Fishman, Y. E. Mandel, L. Barad, H. Domev, D. Kotton, G. Mostoslavsky, O. Binah, and J. Itskovitz-Eldor, Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus. Cell. Reprogram. 12, 665 (2010).
30. R. K. Merling, C. L. Sweeney, U. Choi, S. S. De Ravin, T. G. Myers, F. Otaizo-Carrasquero, J. Pan, G. Linton, L. Chen, S. Koontz, N. L. Theobald, and H. L. Malech, Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 121, e98 (2013).
31. J. M. Churko, P. W. Burridge, and J. C. Wu, Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions. Methods Mol. Biol. 1036, 81 (2013).
32. Y. Wang, J. Liu, X. Tan, G. Li, Y. Gao, X. Liu, L. Zhang, and Y. Li, Induced pluripotent stem cells from human hair follicle mesenchymal stem cells. Stem Cell Rev. 9, 451 (2013).
33. B. A. DeRosa, J. M. Van Baaren, G. K. Dubey, J. M. Lee, M. L. Cuccaro, J. M. Vance, M. A. Pericak-Vance, and D. M. Dykxhoorn, Derivation of autism spectrum disorder-specific induced pluripotent stem cells from peripheral blood mononuclear cells. Neurosci. Lett. 516, 9 (2012).
34. A. Gianotti-Sommer, S. S. Rozelle, S. Sullivan, J. A. Mills, S. M. Park, B. W. Smith, A. M. Iyer, D. L. French, D. N. Kotton, P. Gadue, G. J. Murphy, and G. Mostoslavsky, Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector (2008).
35. J. Yu, M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, Slukvin, II, and J. A. Thomson, Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917 (2007).
36. C. A. Sommer, M. Stadtfeld, G. J. Murphy, K. Hochedlinger, D. N. Kotton, and G. Mostoslavsky, Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27, 543 (2009).
37. E. P. Papapetrou, M. J. Tomishima, S. M. Chambers, Y. Mica, E. Reed, J. Menon, V. Tabar, Q. Mo, L. Studer, and M. Sadelain, Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc. Natl. Acad. Sci. U.S.A. 106, 12759 (2009).
38. C. W. Chang, Y. S. Lai, K. M. Pawlik, K. Liu, C. W. Sun, C. Li, T. R. Schoeb, and T. M. Townes, Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27, 1042 (2009).
39. W. Zhou and C. R. Freed, Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27, 2667 (2009).
40. N. Fusaki, H. Ban, A. Nishiyama, K. Saeki, and M. Hasegawa, Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 85, 348 (2009).
41. W. H. Lai, J. C. Ho, Y. K. Lee, K. M. Ng, K. W. Au, Y. C. Chan, C. P. Lau, H. F. Tse, and C. W. Siu, ROCK inhibition facilitates the generation of human-induced pluripotent stem cells in a defined, feeder-, and serum-free system. Cell. Reprogram. 12, 641 (2010).
42. C. Mummery, D. Ward, C. E. van den Brink, S. D. Bird, P. A. Doevendans, T. Opthof, A. Brutel de la Riviere, L. Tertoolen, M. van der Heyden, and M. Pera, Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat. 200, 233 (2002).
43. R. Passier, D. W. Oostwaard, J. Snapper, J. Kloots, R. J. Hassink, E. Kuijk, B. Roelen, A. B. de la Riviere, and C. Mummery, Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells 23, 772 (2005).
44. L. Yang, M. H. Soonpaa, E. D. Adler, T. K. Roepke, S. J. Kattman, M. Kennedy, E. Henckaerts, K. Bonham, G. W. Abbott, R. M. Linden, L. J. Field, and G. M. Keller, Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453, 524 (2008).
45. X. Lian, C. Hsiao, G. Wilson, K. Zhu, L. B. Hazeltine, S. M. Azarin, K. K. Raval, J. Zhang, T. J. Kamp, and S. P. Palecek, Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. U.S.A. 109, E1848 (2012).
46. X. Lian, J. Zhang, S. M. Azarin, K. Zhu, L. B. Hazeltine, X. Bao, C. Hsiao, T. J. Kamp, and S. P. Palecek, Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat. Protoc. 8, 162 (2013).
47. C. W. Siu, Y. K. Lee, J. C. Ho, W. H. Lai, Y. C. Chan, K. M. Ng, L. Y. Wong, K. W. Au, Y. M. Lau, J. Zhang, K. W. Lay, A. Colman, and H. F. Tse, Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging (Albany NY) 4, 803 (2012).
48. S. Marangoni, C. Di Resta, M. Rocchetti, L. Barile, R. Rizzetto, A. Summa, S. Severi, E. Sommariva, C. Pappone, M. Ferrari, S. Benedetti, and A. Zaza, A Brugada syndrome mutation (p.S216L) and its modulation by p.H558R polymorphism: Standard and dynamic characterization. Cardiovasc. Res. 91, 606 (2011).
49. H. F. Tse, J. C. Ho, S. W. Choi, Y. K. Lee, A. W. Butler, K. M. Ng, C. W. Siu, M. A. Simpson, W. H. Lai, Y. C. Chan, K. W. Au, J. Zhang, K. W. Lay, M. A. Esteban, J. M. Nicholls, A. Colman, and P. C. Sham, Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. Hum. Mol. Genet. 22, 1395 (2013).
50. D. J. Taatjes, M. P. Wadsworth, A. S. Quinn, J. H. Rand, E. G. Bovill, and B. E. Sobel, Imaging aspects of cardiovascular disease at the cell and molecular level. Histochem. Cell. Biol. 130, 235 (2008).
51. E. L. Eskelinen, F. Reggiori, M. Baba, A. L. Kovacs, and P. O. Seglen, Seeing is believing: The impact of electron microscopy on autophagy research. Autophagy 7, 935 (2011).
52. K. K. Rybicka, Glycosomes-The organelles of glycogen metabolism. Tissue Cell. 28, 253 (1996).
53. B. Sakmann and E. Neher, Patch clamp techniques for studying ionic channels in excitable membranes. Annu. Rev. Physiol. 46, 455 (1984).
54. A. Auerbach and F. Sachs, Patch clamp studies of single ionic channels. Annu. Rev. Biophys. Bioeng. 13, 269 (1984).
55. M. E. Spira and A. Hai, Multi-electrode array technologies for neuroscience and cardiology. Nat. Nanotechnol. 8, 83 (2013).
56. I. R. Efimov, V. P. Nikolski, and G. Salama, Optical imaging of the heart. Circ Res. 95, 21 (2004).
57. C. Ding, L. Gepstein, D. T. Nguyen, E. Wilson, G. Hulley, A. Beaser, R. J. Lee, and J. Olgin, High-resolution optical mapping of ventricular tachycardia in rats with chronic myocardial infarction. Pacing Clin. Electrophysiol. 33, 687 (2010).
58. D. T. Nguyen, C. Ding, E. Wilson, G. M. Marcus, and J. E. Olgin, Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 7, 1438 (2010).
59. H. D. T. Himel, G. Bub, P. Lakireddy, and N. El-Sherif, Optical imaging of arrhythmias in the cardiomyocyte monolayer. Heart Rhythm 9, 2077 (2012).
60. V. G. Fast, Simultaneous optical imaging of membrane potential and intracellular calcium. J. Electrocardiol. 38, 107 (2005).
61. T. J. Herron, P. Lee, and J. Jalife, Optical imaging of voltage and calcium in cardiac cells and tissues. Circ. Res. 110, 609 (2012).
62. D. M. O'Malley, B. J. Burbach, and P. R. Adams, Fluorescent calcium indicators: Subcellular behavior and use in confocal imaging. Methods Mol. Biol. 122, 261 (1999).
63. A. Demuro and I. Parker, Optical single-channel recording: imaging Ca2+ flux through individual ion channels with high temporal and spatial resolution. J. Biomed. Opt. 10, 11002 (2005).
64. R. E. Hershberger, D. J. Hedges, and A. Morales, Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 10, 531 (2013).
65. E. L. Burkett and R. E. Hershberger, Clinical and genetic issues in familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 45, 969 (2005).
66. E. Grunig, J. A. Tasman, H. Kucherer, W. Franz, W. Kubler, and H. A. Katus, Frequency and phenotypes of familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 31, 186 (1998).
67. J. B. Goerss, V. V. Michels, J. Burnett, D. J. Driscoll, F. Miller, R. Rodeheffer, A. J. Tajik, and D. Schaid, Frequency of familial dilated cardiomyopathy. Eur. Heart. J. 16, 2 (1995).
68. N. G. Mahon, R. T. Murphy, C. A. MacRae, A. L. Caforio, P. M. Elliott, and W. J. McKenna, Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann. Intern. Med. 143, 108 (2005).
69. A. Gudkova, A. Kostareva, G. Sjoberg, N. Smolina, M. Turalchuk, I. Kuznetsova, M. Rybakova, L. Edstrom, E. Shlyakhto, and T. Sejersen, Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. Pediatr. Cardiol. 34, 467 (2013).
70. C. S. Clemen, H. Herrmann, S. V. Strelkov, and R. Schroder, Desminopathies: Pathology and mechanisms. Acta. Neuropathol. 125, 47 (2013).
71. M. Sam, S. Shah, J. Friden, D. J. Milner, Y. Capetanaki, and R. L. Lieber, Desmin knockout muscles generate lower stress and are less vulnerable to injury compared with wild-type muscles. Am. J. Physiol. Cell Physiol. 279, C1116 (2000).
72. D. J. Milner, G. E. Taffet, X. Wang, T. Pham, T. Tamura, C. Hartley, A. M. Gerdes, and Y. Capetanaki, The absence of desmin leads to cardiomyocyte hypertrophy and cardiac dilation with compromised systolic function. J. Mol. Cell. Cardiol. 31, 2063 (1999).
73. H. M. Becane, G. Bonne, S. Varnous, A. Muchir, V. Ortega, E. H. Hammouda, J. A. Urtizberea, T. Lavergne, M. Fardeau, B. Eymard, S. Weber, K. Schwartz, and D. Duboc, High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin. Electrophysiol. 23, 1661 (2000).
74. C. Meune, J. H. Van Berlo, F. Anselme, G. Bonne, Y. M. Pinto, and D. Duboc, Primary prevention of sudden death in patients with lamin A/C gene mutations. N. Engl. J. Med. 354, 209 (2006).
75. M. Pasotti, C. Klersy, A. Pilotto, N. Marziliano, C. Rapezzi, A. Serio, S. Mannarino, F. Gambarin, V. Favalli, M. Grasso, M. Agozzino, C. Campana, A. Gavazzi, O. Febo, M. Marini, M. Landolina, A. Mortara, G. Piccolo, M. Vigano, L. Tavazzi, and E. Arbustini, Long-term outcome and risk stratification in dilated cardiolaminopathies. J. Am. Coll. Cardiol. 52, 1250 (2008).
76. J. H. van Berlo, W. G. de Voogt, A. J. van der Kooi, J. P. van Tintelen, G. Bonne, R. B. Yaou, D. Duboc, T. Rossenbacker, H. Heidbuchel, M. de Visser, H. J. Crijns, and Y. M. Pinto, Metaanalysis of clinical characteristics of 299 carriers of LMNA gene mutations: Do lamin A/C mutations portend a high risk of sudden death? J. Mol. Med. 83, 79 (2005).
77. L. Dellefave and E. M. McNally, The genetics of dilated cardiomyopathy. Curr. Opin. Cardiol. 25, 198 (2010).
78. D. Fatkin, R. Otway, and Z. Richmond, Genetics of dilated cardiomyopathy. Heart Fail. Clin 6, 129 (2010).
79. J. C. Ho, T. Zhou, W. H. Lai, Y. Huang, Y. C. Chan, X. Li, N. L. Wong, Y. Li, K. W. Au, D. Guo, J. Xu, C. W. Siu, D. Pei, H. F. Tse, and M. A. Esteban, Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging (Albany NY) 3, 380 (2011).
80. A. Muchir, P. Pavlidis, V. Decostre, A. J. Herron, T. Arimura, G. Bonne, and H. J. Worman, Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J. Clin. Invest. 117, 1282 (2007).
81. J. C. Choi, A. Muchir, W. Wu, S. Iwata, S. Homma, J. P. Morrow, and H. J. Worman, Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci. Transl. Med. 4, 144ra102 (2012).
82. N. Ghosh and H. Haddad, Recent progress in the genetics of cardiomyopathy and its role in the clinical evaluation of patients with cardiomyopathy. Curr. Opin. Cardiol. 26, 155 (2011).
83. L. Wang, J. G. Seidman, and C. E. Seidman, Narrative review: Harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann. Intern. Med. 152, 513, W181 (2010).
84. B. J. Maron, Hypertrophic cardiomyopathy: A systematic review. JAMA 287, 1308 (2002).
85. T. Kubo, H. Kitaoka, M. Okawa, T. Hirota, K. Hayato, N. Yamasaki, Y. Matsumura, T. Yabe, J. Takata, and Y. L. Doi, Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. Circ. J. 73, 1599 (2009).
86. A. Keren, P. Syrris, and W. J. McKenna, Hypertrophic cardiomyopathy: The genetic determinants of clinical disease expression. Nat. Clin. Pract. Cardiovasc. Med. 5, 158 (2008).
87. A. A. Geisterfer-Lowrance, M. Christe, D. A. Conner, J. S. Ingwall, F. J. Schoen, C. E. Seidman, and J. G. Seidman, A mouse model of familial hypertrophic cardiomyopathy. Science 272, 731 (1996).
88. A. J. Marian, Y. Wu, D. S. Lim, M. McCluggage, K. Youker, Q. T. Yu, R. Brugada, F. DeMayo, M. Quinones, and R. Roberts, A transgenic rabbit model for human hypertrophic cardiomyopathy. J. Clin. Invest. 104, 1683 (1999).
89. J. C. Tardiff, T. E. Hewett, B. M. Palmer, C. Olsson, S. M. Factor, R. L. Moore, J. Robbins, and L. A. Leinwand, Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J. Clin. Invest. 104, 469 (1999).
90. Z. Gucev, V. Tasic, A. Jancevska, N. Popjordanova, S. Koceva, M. Kuturec, and V. Sabolic, Friedreich ataxia (FA) associated with diabetes mellitus type 1 and hyperthrophic cardiomyopathy. Bosn J. Basic. Med. Sci. 9, 107 (2009).
91. Y. K. Lee, K. M. Ng, W. H. Lai, Y. C. Chan, Y. M. Lau, Q. Lian, H. F. Tse, and C. W. Siu, Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem. Cell. Rev. 7, 976 (2011).
92. S. Klaassen, S. Probst, E. Oechslin, B. Gerull, G. Krings, P. Schuler, M. Greutmann, D. Hurlimann, M. Yegitbasi, L. Pons, M. Gramlich, J. D. Drenckhahn, A. Heuser, F. Berger, R. Jenni, and L. Thierfelder, Mutations in sarcomere protein genes in left ventricular noncompaction. Circulation 117, 2893 (2008).
93. J. P. Kaski, P. Syrris, M. Burch, M. T. Tome-Esteban, M. Fenton, M. Christiansen, P. S. Andersen, N. Sebire, M. Ashworth, J. E. Deanfield, W. J. McKenna, and P. M. Elliott, Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart 94, 1478 (2008).
94. B. Mohapatra, S. Jimenez, J. H. Lin, K. R. Bowles, K. J. Coveler, J. G. Marx, M. A. Chrisco, R. T. Murphy, P. R. Lurie, R. J. Schwartz, P. M. Elliott, M. Vatta, W. McKenna, J. A. Towbin, and N. E. Bowles, Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol. Genet. Metab. 80, 207 (2003).
95. Z. A. Bhuiyan, M. P. van den Berg, J. P. van Tintelen, M. T. Bink-Boelkens, A. C. Wiesfeld, M. Alders, A. V. Postma, I. van Langen, M. M. Mannens, and A. A. Wilde, Expanding spectrum of human RYR2-related disease: New electrocardiographic, structural, and genetic features. Circulation 116, 1569 (2007).
96. M. Moulik, M. Vatta, S. H. Witt, A. M. Arola, R. T. Murphy, W. J. McKenna, A. M. Boriek, K. Oka, S. Labeit, N. E. Bowles, T. Arimura, A. Kimura, and J. A. Towbin, ANKRD1, the gene encoding cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene. J. Am. Coll. Cardiol. 54, 325 (2009).
97. L. Duboscq-Bidot, P. Charron, V. Ruppert, L. Fauchier, A. Richter, L. Tavazzi, E. Arbustini, T. Wichter, B. Maisch, M. Komajda, R. Isnard, E. Villard, and E. H. F. Network, Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. Eur. Heart J. 30, 2128 (2009).
98. H. Morita, H. L. Rehm, A. Menesses, B. McDonough, A. E. Roberts, R. Kucherlapati, J. A. Towbin, J. G. Seidman, and C. E. Seidman, Shared genetic causes of cardiac hypertrophy in children and adults. N. Engl. J. Med. 358, 1899 (2008).
99. S. Daehmlow, J. Erdmann, T. Knueppel, C. Gille, C. Froemmel, M. Hummel, R. Hetzer, and V. Regitz-Zagrosek, Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298, 116 (2002).
100. P. Ehlermann, D. Weichenhan, J. Zehelein, H. Steen, R. Pribe, R. Zeller, S. Lehrke, C. Zugck, B. T. Ivandic, and H. A. Katus, Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med. Genet. 9, 95 (2008).
101. R. E. Hershberger, N. Norton, A. Morales, D. Li, J. D. Siegfried, and J. Gonzalez-Quintana, Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ. Cardiovasc. Genet. 3, 155 (2010).
102. J. T. Granados-Riveron, T. K. Ghosh, M. Pope, F. Bu'Lock, C. Thornborough, J. Eason, E. P. Kirk, D. Fatkin, M. P. Feneley, R. P. Harvey, J. A. Armour, and J. David Brook, Alpha-cardiac myosin heavy chain (MYH6) mutations affecting myofibril formation are associated with congenital heart defects. Hum. Mol. Genet. 19, 4007 (2010).
103. E. Carniel, M. R. Taylor, G. Sinagra, A. Di Lenarda, L. Ku, P. R. Fain, M. M. Boucek, J. Cavanaugh, S. Miocic, D. Slavov, S. L. Graw, J. Feiger, X. Z. Zhu, D. Dao, D. A. Ferguson, M. R. Bristow, and L. Mestroni, Alpha-myosin heavy chain: A sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 112, 54 (2005).
104. E. Rampersaud, J. D. Siegfried, N. Norton, D. Li, E. Martin, and R. E. Hershberger, Rare variant mutations identified in pediatric patients with dilated cardiomyopathy. Prog. Pediatr. Cardiol. 31, 39 (2011).
105. L. Duboscq-Bidot, P. Xu, P. Charron, N. Neyroud, G. Dilanian, A. Millaire, V. Bors, M. Komajda, and E. Villard, Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc. Res. 77, 118 (2008).
106. E. Purevjav, T. Arimura, S. Augustin, A. C. Huby, K. Takagi, S. Nunoda, D. L. Kearney, M. D. Taylor, F. Terasaki, J. M. Bos, S. R. Ommen, H. Shibata, M. Takahashi, M. Itoh-Satoh, W. J. McKenna, R. T. Murphy, S. Labeit, Y. Yamanaka, N. Machida, J. E. Park, P. M. Alexander, R. G. Weintraub, Y. Kitaura, M. J. Ackerman, A. Kimura, and J. A. Towbin, Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum. Mol. Genet. 21, 2039 (2012).
107. T. Hayashi, T. Arimura, M. Itoh-Satoh, K. Ueda, S. Hohda, N. Inagaki, M. Takahashi, H. Hori, M. Yasunami, H. Nishi, Y. Koga, H. Nakamura, M. Matsuzaki, B. Y. Choi, S. W. Bae, C. W. You, K. H. Han, J. E. Park, R. Knoll, M. Hoshijima, K. R. Chien, and A. Kimura, Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44, 2192 (2004).
108. J. Mogensen, R. T. Murphy, T. Shaw, A. Bahl, C. Redwood, H. Watkins, M. Burke, P. M. Elliott, and W. J. McKenna, Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 44, 2033 (2004).
109. J. R. Pinto, J. D. Siegfried, M. S. Parvatiyar, D. Li, N. Norton, M. A. Jones, J. Liang, J. D. Potter, and R. E. Hershberger, Functional characterization of TNNC1 rare variants identified in dilated cardiomyopathy. J. Biol. Chem. 286, 34404 (2011).
110. R. T. Murphy, J. Mogensen, A. Shaw, T. Kubo, S. Hughes, and W. J. McKenna, Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet. 363, 371 (2004).
111. S. Carballo, P. Robinson, R. Otway, D. Fatkin, J. D. Jongbloed, N. de Jonge, E. Blair, J. P. van Tintelen, C. Redwood, and H. Watkins, Identification and functional characterization of cardiac troponin I as a novel disease gene in autosomal dominant dilated cardiomyopathy. Circ. Res. 105, 375 (2009).
112. M. Hirtle-Lewis, K. Desbiens, I. Ruel, N. Rudzicz, J. Genest, J. C. Engert, and N. Giannetti, The genetics of dilated cardiomyopathy: A prioritized candidate gene study of LMNA, TNNT2, TCAP, and PLN. Clin. Cardiol. 36, 628 (2013).
113. N. K. Lakdawala, L. Dellefave, C. S. Redwood, E. Sparks, A. L. Cirino, S. Depalma, S. D. Colan, B. Funke, R. S. Zimmerman, P. Robinson, H. Watkins, C. E. Seidman, J. G. Seidman, E. M. McNally, and C. Y. Ho, Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J. Am. Coll. Cardiol. 55, 320 (2010).
114. B. Gerull, M. Gramlich, J. Atherton, M. McNabb, K. Trombitas, S. Sasse-Klaassen, J. G. Seidman, C. Seidman, H. Granzier, S. Labeit, M. Frenneaux, and L. Thierfelder, Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30, 201 (2002).
115. G. Yoskovitz, Y. Peled, M. Gramlich, H. Lahat, H. Resnik-Wolf, M. S. Feinberg, A. Afek, E. Pras, M. Arad, B. Gerull, and D. Freimark, A novel titin mutation in adult-onset familial dilated cardiomyopathy. Am. J. Cardiol. 109, 1644 (2012).
116. M. M. DeWitt, H. M. MacLeod, B. Soliven, and E. M. McNally, Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1396 (2006).
117. P. A. van der Zwaag, I. A. van Rijsingen, A. Asimaki, J. D. Jongbloed, D. J. van Veldhuisen, A. C. Wiesfeld, M. G. Cox, L. T. van Lochem, R. A. de Boer, R. M. Hofstra, I. Christiaans, K. Y. van Spaendonck-Zwarts, R. H. Lekanne dit Deprez, D. P. Judge, H. Calkins, A. J. Suurmeijer, R. N. Hauer, J. E. Saffitz, A. A. Wilde, M. P. van den Berg, and J. P. van Tintelen, Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: Evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199 (2012).
118. J. A. Schmitt, E. Hogervorst, E. F. Vuurman, J. Jolles, and W. J. Riedel, Memory functions and focussed attention in middle-aged and elderly subjects are unaffected by a low, acute dose of caffeine. J. Nutr. Health Aging. 7, 301 (2003).
119. C. Sainte Beuve, P. D. Allen, G. Dambrin, F. Rannou, I. Marty, P. Trouve, V. Bors, A. Pavie, I. Gandgjbakch, and D. Charlemagne, Cardiac calcium release channel (ryanodine receptor) in control and cardiomyopathic human hearts: mRNA and protein contents are differentially regulated. J. Mol. Cell. Cardiol. 29, 1237 (1997).
120. M. Bienengraeber, T. M. Olson, V. A. Selivanov, E. C. Kathmann, F. O'Cochlain, F. Gao, A. B. Karger, J. D. Ballew, D. M. Hodgson, L. V. Zingman, Y. P. Pang, A. E. Alekseev, and A. Terzic, ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36, 382 (2004).
121. T. F. Solbach, J. Konig, M. F. Fromm, and O. Zolk, ATP-binding cassette transporters in the heart. Trends Cardiovasc. Med. 16, 7 (2006).
122. M. Hesse, C. S. Kondo, R. B. Clark, L. Su, F. L. Allen, C. T. Geary-Joo, S. Kunnathu, D. L. Severson, A. Nygren, W. R. Giles, and J. C. Cross, Dilated cardiomyopathy is associated with reduced expression of the cardiac sodium channel Scn5a. Cardiovasc. Res. 75, 498 (2007).
123. W. P. McNair, L. Ku, M. R. Taylor, P. R. Fain, D. Dao, E. Wolfel, L. Mestroni, and G. Familial Cardiomyopathy Registry Research, SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 110, 2163 (2004).
124. M. R. Taylor, D. Slavov, L. Ku, A. Di Lenarda, G. Sinagra, E. Carniel, K. Haubold, M. M. Boucek, D. Ferguson, S. L. Graw, X. Zhu, J. Cavanaugh, C. C. Sucharov, C. S. Long, M. R. Bristow, P. Lavori, L. Mestroni, R. Familial Cardiomyopathy, and B. D. Bank, Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 115, 1244 (2007).
125. G. Sjoberg, C. A. Saavedra-Matiz, D. R. Rosen, E. M. Wijsman, K. Borg, S. H. Horowitz, and T. Sejersen, A missense mutation in the desmin rod domain is associated with autosomal dominant distal myopathy, and exerts a dominant negative effect on filament formation. Hum. Mol. Genet. 8, 2191 (1999).
126. F. Muntoni, M. Cau, A. Ganau, R. Congiu, G. Arvedi, A. Mateddu, M. G. Marrosu, C. Cianchetti, G. Realdi, A. Cao, and M. A. Melis, Brief report: Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N. Engl. J. Med. 329, 921 (1993).
127. J. A. Towbin, J. F. Hejtmancik, P. Brink, B. Gelb, X. M. Zhu, J. S. Chamberlain, E. R. McCabe, and M. Swift, X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87, 1854 (1993).
128. A. Todorova, D. Constantinova, and I. Kremensky, Dilated cardiomyopathy and new 16 bp deletion in exon 44 of the Dystrophin gene: The possible role of repeated motifs in mutation generation. Am. J. Med. Genet A. 120A, 5 (2003).
129. K. Yoshida, A. Nakamura, M. Yazaki, S. Ikeda, and S. Takeda, Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy. Hum. Mol. Genet. 7, 1129 (1998).
130. M. Maeda, E. Holder, B. Lowes, S. Valent, and R. D. Bies, Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation 95, 17 (1997).
131. T. M. Olson, S. Illenberger, N. Y. Kishimoto, S. Huttelmaier, M. T. Keating, and B. M. Jockusch, Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 105, 431 (2002).
132. R. Bauer, J. Hudson, H. D. Muller, C. Sommer, G. Dekomien, J. Bourke, D. Routledge, K. Bushby, J. Klepper, and V. Straub, Does delta-sarcoglycan- associated autosomal-dominant cardiomyopathy exist? Eur. J. Hum. Genet. 17, 1148 (2009).
133. S. Tsubata, K. R. Bowles, M. Vatta, C. Zintz, J. Titus, L. Muhonen, N. E. Bowles, and J. A. Towbin, Mutations in the human deltasarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 106, 655 (2000).
134. S. Karkkainen, R. Miettinen, P. Tuomainen, P. Karkkainen, T. Helio, E. Reissell, M. Kaartinen, L. Toivonen, M. S. Nieminen, J. Kuusisto, M. Laakso, and K. Peuhkurinen, A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy. J. Mol. Med. (Berl). 81, 795 (2003).
135. D. Fatkin, C. MacRae, T. Sasaki, M. R. Wolff, M. Porcu, M. Frenneaux, J. Atherton, H. J. Vidaillet, Jr., S. Spudich, U. De Girolami, J. G. Seidman, C. Seidman, F. Muntoni, G. Muehle, W. Johnson, and B. McDonough, Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 341, 1715 (1999).
136. R. Al-Saaidi, T. B. Rasmussen, J. Palmfeldt, P. H. Nissen, A. Beqqali, J. Hansen, Y. M. Pinto, T. Boesen, J. Mogensen, and P. Bross, The LMNA mutation p.Arg321Ter associated with dilated cardiomyopathy leads to reduced expression and a skewed ratio of lamin A and lamin C proteins. Exp. Cell Res. 319, 3010 (2013).
137. D. Ronvelia, J. Greenwood, J. Platt, S. Hakim, and M. V. Zaragoza, Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle. Mol. Genet. Metab. 107, 428 (2012).
138. A. N. Brady, B. M. Shehata, and P. M. Fernhoff, X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene. Prenat. Diagn. 26, 462 (2006).
139. P. D'Adamo, L. Fassone, A. Gedeon, E. A. Janssen, S. Bione, P. A. Bolhuis, P. G. Barth, M. Wilson, E. Haan, K. H. Orstavik, M. A. Patton, A. J. Green, E. Zammarchi, M. A. Donati, and D. Toniolo, The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am. J. Hum. Genet. 61, 862 (1997).
140. P. Syrris, D. Ward, A. Evans, A. Asimaki, E. Gandjbakhch, S. Sen-Chowdhry, and W. J. McKenna, Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am. J. Hum. Genet. 79, 978 (2006).
141. P. Elliott, C. O'Mahony, P. Syrris, A. Evans, C. Rivera Sorensen, M. N. Sheppard, G. Carr-White, A. Pantazis, and W. J. McKenna, Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ. Cardiovasc. Genet. 3, 314 (2010).
142. M. G. Posch, M. J. Posch, C. Geier, B. Erdmann, W. Mueller, A. Richter, V. Ruppert, S. Pankuweit, B. Maisch, A. Perrot, J. Buttgereit, R. Dietz, W. Haverkamp, and C. Ozcelik, A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy. Mol Genet Metab. 95, 74 (2008).
143. E. E. Norgett, T. W. Lucke, B. Bowers, C. S. Munro, I. M. Leigh, and D. P. Kelsell, Early death from cardiomyopathy in a family with autosomal dominant striate palmoplantar keratoderma and woolly hair associated with a novel insertion mutation in desmoplakin. J. Invest. Dermatol. 126, 1651 (2006).
144. T. B. Rasmussen, J. Hansen, P. H. Nissen, J. Palmfeldt, S. Dalager, U. B. Jensen, W. Y. Kim, L. Heickendorff, H. Molgaard, H. K. Jensen, K. E. Sorensen, U. T. Baandrup, P. Bross, and J. Mogensen, Protein expression studies of desmoplakin mutations in cardiomyopathy patients reveal different molecular disease mechanisms. Clin. Genet. 84, 20 (2013).
145. M. R. Taylor, L. Ku, D. Slavov, J. Cavanaugh, M. Boucek, X. Zhu, S. Graw, E. Carniel, C. Barnes, D. Quan, R. Prall, M. A. Lovell, G. Mierau, P. Ruegg, N. Mandava, M. R. Bristow, J. A. Towbin, L. Mestroni, and R. Familial Cardiomyopathy, Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J. Hum. Genet. 52, 830 (2007).
146. S. Sugimoto, K. Shiomi, A. Yamamoto, I. Nishino, I. Nonaka, and T. Ohi, LAMP-2 positive vacuolar myopathy with dilated cardiomyopathy. Intern. Med. 46, 757 (2007).
147. N. Norton, D. Li, M. J. Rieder, J. D. Siegfried, E. Rampersaud, S. Zuchner, S. Mangos, J. Gonzalez-Quintana, L. Wang, S. McGee, J. Reiser, E. Martin, D. A. Nickerson, and R. E. Hershberger, Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am. J. Hum. Genet. 88, 273 (2011).
148. S. Labeit, BAG3 in heart disease: Novel clues for cardiomyocyte survival from the Z-disk? Hum. Mutat. 32, iv (2011).
149. N. Inagaki, T. Hayashi, T. Arimura, Y. Koga, M. Takahashi, H. Shibata, K. Teraoka, T. Chikamori, A. Yamashina, and A. Kimura, Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 342, 379 (2006).
150. P. Reilich, B. Schoser, N. Schramm, S. Krause, J. Schessl, W. Kress, J. Muller-Hocker, M. C. Walter, and H. Lochmuller, The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. Neuromuscul. Disord. 20, 255 (2010).
151. D. Li, S. B. Parks, J. D. Kushner, D. Nauman, D. Burgess, S. Ludwigsen, J. Partain, R. R. Nixon, C. N. Allen, R. P. Irwin, P. M. Jakobs, M. Litt, and R. E. Hershberger, Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 79, 1030 (2006).
152. R. Knoll, M. Hoshijima, H. M. Hoffman, V. Person, I. Lorenzen-Schmidt, M. L. Bang, T. Hayashi, N. Shiga, H. Yasukawa, W. Schaper, W. McKenna, M. Yokoyama, N. J. Schork, J. H. Omens, A. D. McCulloch, A. Kimura, C. C. Gregorio, W. Poller, J. Schaper, H. P. Schultheiss, and K. R. Chien, The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111, 943 (2002).
153. S. Arber, J. J. Hunter, J. Ross, Jr., M. Hongo, G. Sansig, J. Borg, J. C. Perriard, K. R. Chien, and P. Caroni, MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 88, 393 (1997).
154. T. M. Olson, T. P. Doan, N. Y. Kishimoto, F. G. Whitby, M. J. Ackerman, and L. Fananapazir, Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 32, 1687 (2000).
155. C. Gruner, M. Care, K. Siminovitch, G. Moravsky, E. D. Wigle, A. Woo, and H. Rakowski, Sarcomere protein gene mutations in patients with apical hypertrophic cardiomyopathy. Circ. Cardiovasc. Genet. 4, 288 (2011).
156. M. Arad, M. Penas-Lado, L. Monserrat, B. J. Maron, M. Sherrid, C. Y. Ho, S. Barr, A. Karim, T. M. Olson, M. Kamisago, J. G. Seidman, and C. E. Seidman, Gene mutations in apical hypertrophic cardiomyopathy. Circulation 112, 2805 (2005).
157. H. Watkins, D. Conner, L. Thierfelder, J. A. Jarcho, C. MacRae, W. J. McKenna, B. J. Maron, J. G. Seidman, and C. E. Seidman, Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 11, 434 (1995).
158. B. Yu, J. A. French, L. Carrier, R. W. Jeremy, D. R. McTaggart, M. R. Nicholson, B. Hambly, C. Semsarian, D. R. Richmond, K. Schwartz, and R. J. Trent, Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. J. Med. Genet. 35, 205 (1998).
159. L. Nunez, J. R. Gimeno-Blanes, M. I. Rodriguez-Garcia, L. Monserrat, E. Zorio, C. Coats, C. G. McGregor, J. P. Hernandez del Rincon, A. Castro-Beiras, and M. Hermida-Prieto, Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circ. J. 77, 2358 (2013).
160. S. D. Solomon, A. A. T. Geisterfer-Lowrance, H. P. Vosberg, G. Hiller, J. A. Jarcho, C. C. Morton, W. O. McBride, A. L. Mitchell, A. E. Bale, W. J. McKenna, J. G. Seidman, and C. E. Seidman, A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12. Am. J. Hum. Genet. 47, 389 (1990).
161. J. Flavigny, P. Richard, R. Isnard, L. Carrier, P. Charron, G. Bonne, J. F. Forissier, M. Desnos, O. Dubourg, M. Komajda, K. Schwartz, and B. Hainque, Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J. Mol. Med (Berl). 76, 208 (1998).
162. Z. T. Kabaeva, A. Perrot, B. Wolter, R. Dietz, N. Cardim, J. M. Correia, H. D. Schulte, A. A. Aldashev, M. M. Mirrakhimov, and K. J. Osterziel, Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. Eur. J. Hum. Genet. 10, 741 (2002).
163. A. Jay, R. Chikarmane, J. Poulik, and V. K. Misra, Infantile hypertrophic cardiomyopathy associated with a novel MYL3 mutation. Cardiology 124, 248 (2013).
164. P. S. Andersen, P. L. Hedley, S. P. Page, P. Syrris, J. C. Moolman-Smook, W. J. McKenna, P. M. Elliott, and M. Christiansen, A novel Myosin essential light chain mutation causes hypertrophic cardiomyopathy with late onset and low expressivity. Biochem. Res. Int. 2012, 685108 (2012).
165. K. Elliott, H. Watkins, and C. S. Redwood, Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J. Biol. Chem. 275, 22069 (2000).
166. A. Kimura, H. Harada, J. E. Park, H. Nishi, M. Satoh, M. Takahashi, S. Hiroi, T. Sasaoka, N. Ohbuchi, T. Nakamura, T. Koyanagi, T. H. Hwang, J. A. Choo, K. S. Chung, A. Hasegawa, R. Nagai, O. Okazaki, H. Nakamura, M. Matsuzaki, T. Sakamoto, H. Toshima, Y. Koga, T. Imaizumi, and T. Sasazuki, Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 16, 379 (1997).
167. J. C. Moon, J. Mogensen, P. M. Elliott, G. C. Smith, A. G. Elkington, S. K. Prasad, D. J. Pennell, and W. J. McKenna, Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91, 1036 (2005).
168. J. F. Forissier, L. Carrier, H. Farza, G. Bonne, J. Bercovici, P. Richard, B. Hainque, P. J. Townsend, M. H. Yacoub, S. Faure, O. Dubourg, A. Millaire, A. A. Hagege, M. Desnos, M. Komajda, and K. Schwartz, Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation 94, 3069 (1996).
169. L. Thierfelder, H. Watkins, C. MacRae, R. Lamas, W. McKenna, H. P. Vosberg, J. G. Seidman, and C. E. Seidman, Alphatropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell 77, 701 (1994).
170. C. Geier, A. Perrot, C. Ozcelik, P. Binner, D. Counsell, K. Hoffmann, B. Pilz, Y. Martiniak, K. Gehmlich, P. F. van der Ven, D. O. Furst, A. Vornwald, E. von Hodenberg, P. Nurnberg, T. Scheffold, R. Dietz, and K. J. Osterziel, Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107, 1390 (2003).
171. B. Newman, D. Cescon, A. Woo, H. Rakowski, M. J. Erikkson, M. Sole, E. D. Wigle, and K. A. Siminovitch, W4R variant in CSRP3 encoding muscle LIM protein in a patient with hypertrophic cardiomyopathy. Mol. Genet. Metab. 84, 374 (2005).
172. J. M. Bos, R. N. Poley, M. Ny, D. J. Tester, X. Xu, M. Vatta, J. A. Towbin, B. J. Gersh, S. R. Ommen, and M. J. Ackerman, Genotypephenotype relationships involving hypertrophic cardiomyopathyassociated mutations in titin, muscle LIM protein, and telethonin. Mol. Genet. Metab. 88, 78 (2006).
173. F. W. Friedrich, B. R. Wilding, S. Reischmann, C. Crocini, P. Lang, P. Charron, O. J. Muller, M. J. McGrath, I. Vollert, A. Hansen, W. A. Linke, C. Hengstenberg, G. Bonne, S. Morner, T. Wichter, H. Madeira, E. Arbustini, T. Eschenhagen, C. A. Mitchell, R. Isnard, and L. Carrier, Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum. Mol. Genet. 21, 3237 (2012).
174. H. Hartmannova, M. Kubanek, M. Sramko, L. Piherova, L. Noskova, K. Hodanova, V. Stranecky, A. Pristoupilova, J. Sovova, T. Marek, J. Maluskova, P. Ridzon, J. Kautzner, H. Hulkova, and S. Kmoch, Isolated X-linked hypertrophic cardiomyopathy caused by a novel mutation of the four-and-a-half LIM domain 1 gene. Circ. Cardiovasc. Genet. 6, 543 (2013).
175. R. M. Payne and G. R. Wagner, Cardiomyopathy in Friedreich ataxia: Clinical findings and research. J. Child. Neurol. 27, 1179 (2012).
176. F. Ahmad, J. G. Seidman, and C. E. Seidman, The genetic basis for cardiac remodeling. Annu. Rev. Genomics Hum. Genet. 6, 185 (2005).
177. N. Nakagawa, H. Maruyama, T. Ishihara, U. Seino, J. Kawabe, F. Takahashi, M. Kobayashi, A. Yamauchi, Y. Sasaki, N. Sakamoto, H. Ota, Y. Tanabe, T. Takeuchi, T. Takenaka, K. Kikuchi, and N. Hasebe, Clinical and genetic investigation of a Japanese family with cardiac fabry disease. Identification of a novel alphagalactosidase A missense mutation (G195V). Int. Heart J. 52, 308 (2011).
178. M. Arad, B. J. Maron, J. M. Gorham, W. H. Johnson, Jr., J. P. Saul, A. R. Perez-Atayde, P. Spirito, G. B. Wright, R. J. Kanter, C. E. Seidman, and J. G. Seidman, Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N. Engl. J. Med. 352, 362 (2005).
179. P. Charron, E. Villard, P. Sebillon, P. Laforet, T. Maisonobe, L. Duboscq-Bidot, N. Romero, V. Drouin-Garraud, T. Frebourg, P. Richard, B. Eymard, and M. Komajda, Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart 90, 842 (2004).
180. Z. Yang, C. J. McMahon, L. R. Smith, J. Bersola, A. M. Adesina, J. P. Breinholt, D. L. Kearney, W. J. Dreyer, S. W. Denfield, J. F. Price, M. Grenier, N. J. Kertesz, S. K. Clunie, S. D. Fernbach, J. F. Southern, S. Berger, J. A. Towbin, K. R. Bowles, and N. E. Bowles, Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 112, 1612 (2005).
181. E. Blair, C. Redwood, H. Ashrafian, M. Oliveira, J. Broxholme, B. Kerr, A. Salmon, I. Ostman-Smith, and H. Watkins, Mutations in the gamma (2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10, 1215 (2001).
182. S. M. Oliveira, J. Ehtisham, C. S. Redwood, I. Ostman-Smith, E. M. Blair, and H. Watkins, Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathies: Implications for kinase function and disease pathogenesis. J. Mol. Cell. Cardiol. 35, 1251 (2003).
183. P. Laforet, P. Richard, M. A. Said, N. B. Romero, E. Lacene, J. P. Leroy, C. Baussan, J. Y. Hogrel, T. Lavergne, K. Wahbi, B. Hainque, and D. Duboc, A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul. Disord. 16, 178 (2006).
184. W. P. Yang, P. C. Levesque, W. A. Little, M. L. Conder, F. Y. Shalaby, and M. A. Blanar, KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc. Natl. Acad. Sci. U.S.A. 94, 4017 (1997).
185. M. H. van den Berg, A. A. Wilde, E. O. Robles de Medina, H. Meyer, J. L. Geelen, R. J. Jongbloed, H. J. Wellens, and J. P. Geraedts, The long QT syndrome: A novel missense mutation in the S6 region of the KVLQT1 gene. Hum. Genet. 100, 356 (1997).
186. Q. Wang, M. E. Curran, I. Splawski, T. C. Burn, J. M. Millholland, T. J. VanRaay, J. Shen, K. W. Timothy, G. M. Vincent, T. de Jager, P. J. Schwartz, J. A. Toubin, A. J. Moss, D. L. Atkinson, G. M. Landes, T. D. Connors, and M. T. Keating, Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12, 17 (1996).
187. D. M. Roden, R. Lazzara, M. Rosen, P. J. Schwartz, J. Towbin, and G. M. Vincent, Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 94, 1996 (1996).
188. R. Dumaine, Q. Wang, M. T. Keating, H. A. Hartmann, P. J. Schwartz, A. M. Brown, and G. E. Kirsch, Multiple mechanisms of Na+ channel - Linked long-QT syndrome. Circ Res 78, 916 (1996).
189. M. E. Curran, I. Splawski, K. W. Timothy, G. M. Vincent, E. D. Green, and M. T. Keating, A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795 (1995).
190. Q. Wang, J. Shen, I. Splawski, D. Atkinson, Z. Li, J. L. Robinson, A. J. Moss, J. A. Towbin, and M. T. Keating, SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 8, 805 (1995).
191. P. J. Mohler, J. J. Schott, A. O. Gramolini, K. W. Dilly, S. Guatimosim, W. H. duBell, L. S. Song, K. Haurogne, F. Kyndt, M. E. Ali, T. B. Rogers, W. J. Lederer, D. Escande, H. Le Marec, and V. Bennett, Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421, 634 (2003).
192. P. J. Mohler, I. Splawski, C. Napolitano, G. Bottelli, L. Sharpe, K. Timothy, S. G. Priori, M. T. Keating, and V. Bennett, A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc. Natl. Acad. Sci. U.S.A. 101, 9137 (2004).
193. S. M. Hashemi, T. J. Hund, and P. J. Mohler, Cardiac ankyrins in health and disease. J. Mol. Cell. Cardiol. 47, 203 (2009).
194. I. Splawski, M. Tristani-Firouzi, M. H. Lehmann, M. C. Sanguinetti, and M. T. Keating, Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat. Genet. 17, 338 (1997).
195. J. Temple, P. Frias, J. Rottman, T. Yang, Y. Wu, E. E. Verheijck, W. Zhang, C. Siprachanh, H. Kanki, J. B. Atkinson, P. King, M. E. Anderson, S. Kupershmidt, and D. M. Roden, Atrial fibrillation in KCNE1-null mice. Circ. Res. 97, 62 (2005).
196. G. W. Abbott, F. Sesti, I. Splawski, M. E. Buck, M. H. Lehmann, K. W. Timothy, M. T. Keating, and S. A. Goldstein, MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97, 175 (1999).
197. Y. Lu, M. P. Mahaut-Smith, C. L. Huang, and J. I. Vandenberg, Mutant MiRP1 subunits modulate HERG K+ channel gating: A mechanism for pro-arrhythmia in long QT syndrome type 6. J. Physiol. 551, 253 (2003).
198. N. M. Plaster, R. Tawil, M. Tristani-Firouzi, S. Canun, S. Bendahhou, A. Tsunoda, M. R. Donaldson, S. T. Iannaccone, E. Brunt, R. Barohn, J. Clark, F. Deymeer, A. L. George, Jr., F. A. Fish, A. Hahn, A. Nitu, C. Ozdemir, P. Serdaroglu, S. H. Subramony, G. Wolfe, Y. H. Fu, and L. J. Ptacek, Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105, 511 (2001).
199. H. Fodstad, H. Swan, M. Auberson, I. Gautschi, J. Loffing, L. Schild, and K. Kontula, Loss-of-function mutations of the K(+) channel gene KCNJ2 constitute a rare cause of long QT syndrome. J. Mol. Cell. Cardiol. 37, 593 (2004).
200. I. Splawski, K. W. Timothy, N. Decher, P. Kumar, F. B. Sachse, A. H. Beggs, M. C. Sanguinetti, and M. T. Keating, Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Natl. Acad. Sci. USA 102, 8089; discussion 8086-8088 (2005).
201. M. Vatta, M. J. Ackerman, B. Ye, J. C. Makielski, E. E. Ughanze, E. W. Taylor, D. J. Tester, R. C. Balijepalli, J. D. Foell, Z. Li, T. J. Kamp, and J. A. Towbin, Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114, 2104 (2006).
202. L. B. Cronk, B. Ye, T. Kaku, D. J. Tester, M. Vatta, J. C. Makielski, and M. J. Ackerman, Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm. 4, 161 (2007).
203. A. Medeiros-Domingo, T. Kaku, D. J. Tester, P. Iturralde-Torres, A. Itty, B. Ye, C. Valdivia, K. Ueda, S. Canizales-Quinteros, M. T. Tusie-Luna, J. C. Makielski, and M. J. Ackerman, SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 116, 134 (2007).
204. B. H. Tan, K. N. Pundi, D. W. Van Norstrand, C. R. Valdivia, D. J. Tester, A. Medeiros-Domingo, J. C. Makielski, and M. J. Ackerman, Sudden infant death syndrome-associated mutations in the sodium channel beta subunits. Heart Rhythm. 7, 771 (2010).
205. L. Chen, M. L. Marquardt, D. J. Tester, K. J. Sampson, M. J. Ackerman, and R. S. Kass, Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 104, 20990 (2007).
206. L. Chen and R. S. Kass, A-kinase anchoring protein 9 and IKs channel regulation. J. Cardiovasc. Pharmacol. 58, 459 (2011).
207. K. Ueda, C. Valdivia, A. Medeiros-Domingo, D. J. Tester, M. Vatta, G. Farrugia, M. J. Ackerman, and J. C. Makielski, Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc. Natl. Acad. Sci. U.S.A. 105, 9355 (2008).
208. G. Wu, T. Ai, J. J. Kim, B. Mohapatra, Y. Xi, Z. Li, S. Abbasi, E. Purevjav, K. Samani, M. J. Ackerman, M. Qi, A. J. Moss, W. Shimizu, J. A. Towbin, J. Cheng, and M. Vatta, alpha-1-syntrophin mutation and the long-QT syndrome: A disease of sodium channel disruption. Circ. Arrhythm. Electrophysiol. 1, 193 (2008).
209. Y. Yang, Y. Yang, B. Liang, J. Liu, J. Li, M. Grunnet, S. P. Olesen, H. B. Rasmussen, P. T. Ellinor, L. Gao, X. Lin, L. Li, L. Wang, J. Xiao, Y. Liu, Y. Liu, S. Zhang, D. Liang, L. Peng, T. Jespersen, and Y. H. Chen, Identification of a Kir3.4 mutation in congenital long QT syndrome. Am. J. Hum. Genet. 86, 872 (2010).
210. F. Wang, J. Liu, L. Hong, B. Liang, C. Graff, Y. Yang, M. Christiansen, S. P. Olesen, L. Zhang, and J. K. Kanters, The phenotype characteristics of type 13 long QT syndrome with mutation in KCNJ5 (Kir3.4-G387R). Heart Rhythm 10, 1500 (2013).
211. Y. K. Lee, P. W. Ho, R. Schick, Y. M. Lau, W. H. Lai, T. Zhou, Y. Li, K. M. Ng, S. L. Ho, M. A. Esteban, O. Binah, H. F. Tse, and C. W. Siu, Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells. Pflugers Arch. Epub ahead of print (2013).
212. Y. K. Lee and C. W. Siu, Calcium Handling in hiPSC-derived Cardiomyocytes. Springer-Brief Epub ahead of print (2012).